In this phase 3 trial , we randomly assigned 487 adults with newly diagnosed mantle-cell lymphoma who were ineligible or not considered for stem-cell transplantation to receive six to eight 21-day cycles of R-CHOP intravenously on day 1 ( with prednisone administered orally on days 1 to 5 ) or VR-CAP ( R-CHOP regimen , but replacing vincristine with bortezomib at a dose of 1.3 mg per square meter of body-surface area on days 1 , 4 , 8 , and 11 ) .